Metastases

Oncology·MeSH: Lung Neoplasms

15 drugs in development·14 companies·3 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
metastron	Q BioMed Inc. (QBIO)
sonalleve	Profound Medical Corp. (PROF)
strontium-89	Q BioMed Inc. (QBIO)
tukysa	Seagen Inc. (SGEN)
zoledronic acid	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(2)

Drug	Company
A10 and AS2-1 Antineoplaston	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Zipalertinib (CLN-081/TAS6417)	Cullinan Therapeutics, Inc. (CGEM)

Phase 2(4)

Drug	Company
Encorafenib	ADMA BIOLOGICS, INC. (ADMA)
rad101	Radiopharm Theranostics Limited (RADX)
reyobiq	PLUS THERAPEUTICS Inc. (PSTV)
utidelone	BIOSTAR PHARMACEUTICALS, INC. (BSPM)

Unknown(2)

Drug	Company
EndoPredict	MYRIAD GENETICS INC (MYGN)
HLX14	Organon & Co. (OGN)

Phase 4(2)

Drug	Company
Leucovorin	IGM Biosciences, Inc. (IGMS)
Memantine	SUPERNUS PHARMACEUTICALS, INC. (SUPN)

BioSniper tracks 15 drugs in development for Metastases across 14 companies.

There are 3 clinical trials targeting Metastases tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.